Skip to content

Study · Not a test of the peptide alone · 2025

4 results

Design and implication of a breast cancer-targeted drug delivery system utilizing the Kisspeptin/GPR54 system.

Nie Y, Wei Y, Zhang Y, Liang Z, Lei Z, Chang M, Peng Y

International journal of pharmaceutics2 Jan 2025Cited by 2 (Europe PMC)

PMID39755342 (opens in a new tab)DOI10.1016/j.ijpharm.2024.125154 (opens in a new tab)PepBankPUB-39755342
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Kisspeptin-10 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Kisspeptin-10.

  1. 01AnimalNot a test of Kisspeptin-10 aloneAnimal study (in vivo)Activity measurement

    In mice with breast tumors, liposomes surface-modified with Kp-10-228 showed enhanced accumulation in tumor cells.

    In plain wordsIn mice with breast tumors, liposomes tagged with a kisspeptin analog built up more in tumor cells.

    Peptide
    Kisspeptin-10
    Outcome
    IncreaseLiposome accumulation in tumor in vivo
    Study

    mousen: not reported in source

    Mice with breast tumors
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    By surface-modifying liposomes with Kp-10-228 (228-K3-EG8-Liposome), we demonstrated enhanced accumulation of these liposomes in tumor cells, both in vitro and in vivo.

    In this study, Kisspeptin-10 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Kisspeptin-10.

  2. 02AnimalNot a test of Kisspeptin-10 aloneAnimal study (in vivo)Efficacy outcome

    In mice with breast tumors, doxorubicin-loaded Kp-10-228 liposomes significantly extended median survival compared with non-targeted liposomes or free doxorubicin.

    In plain wordsIn mice with breast tumors, doxorubicin-loaded liposomes tagged with a kisspeptin analog extended survival more than untagged liposomes or free doxorubicin.

    Peptide
    Kisspeptin-10
    Outcome
    IncreaseMedian survival time
    Study

    mousen: not reported in source

    Mice with breast tumors
    Comparator
    Non-targeted liposomes or free doxorubicin
    Outcome group
    Mortality · Cancer

    Source sentences

    Summary
    significantly extending the median survival time in mice with breast tumors compared to model mice treated with non-targeted liposomes or free doxorubicin.

    In this study, Kisspeptin-10 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Kisspeptin-10.

  3. 03LabNot a test of Kisspeptin-10 aloneIn vitro (cells)Activity measurement

    In breast cancer cells, liposomes surface-modified with Kp-10-228 showed enhanced accumulation in tumor cells.

    In plain wordsIn breast cancer cells in the lab, liposomes tagged with a kisspeptin analog built up more in the cancer cells.

    Peptide
    Kisspeptin-10
    Outcome
    IncreaseLiposome accumulation in tumor cells in vitro
    Study

    n: not reported in source

    Breast cancer cells
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    By surface-modifying liposomes with Kp-10-228 (228-K3-EG8-Liposome), we demonstrated enhanced accumulation of these liposomes in tumor cells, both in vitro and in vivo.

    In this study, Kisspeptin-10 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Kisspeptin-10.

  4. 04LabNot a test of Kisspeptin-10 aloneIn vitro (cells)Efficacy outcome

    In breast cancer cells, doxorubicin-loaded Kp-10-228 liposomes strongly inhibited cell proliferation.

    In plain wordsIn breast cancer cells in the lab, doxorubicin-loaded liposomes tagged with a kisspeptin analog strongly slowed cell growth.

    Peptide
    Kisspeptin-10
    Outcome
    DecreaseCancer cell proliferation
    Study

    n: not reported in source

    Breast cancer cells
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    Doxorubicin-loaded 228-K3-EG8-Liposome exhibited a remarkable inhibition of cancer cell proliferation

    In this study, Kisspeptin-10 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Kisspeptin-10.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.